Brain and Cognition Discovery Foundation, Toronto, ON, Canada.
Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada.
Curr Med Res Opin. 2024 Aug;40(8):1407-1411. doi: 10.1080/03007995.2024.2374510. Epub 2024 Jul 8.
Post-COVID-19 condition (PCC), also known as "long COVID," is characterized by persistent symptoms, negatively affecting the well-being of individuals with PCC. Anhedonia (i.e. reduced capacity for pleasure) and compromised psychosocial functioning are notable symptoms in those with PCC. We aimed to provide insights to understand the effects of anhedonia and impaired psychosocial functioning of individuals with PCC.
This post-hoc analysis used data from an 8-week, double-blind, randomized, placebo-controlled trial which evaluated vortioxetine for cognitive deficits in individuals with PCC (Clinicaltrials.gov Identifier: NCT05047952). A total of 147 eligible participants were randomly assigned to receive vortioxetine or matching placebo over eight weeks of double-blind treatment. Our study investigated the relationship between anhedonia, assessed by the Snaith-Hamilton Pleasure Scale (SHAPS), and psychosocial functioning, measured with the Post-COVID Functional Status (PCFS) scale. The analysis was conducted using a generalized linear model, with adjustments for relevant covariates such as age, sex, education, suspected versus confirmed COVID diagnosis, MDD diagnosis, and alcohol consumption.
Of the 147 participants, 143 participants had available baseline data for analysis. We observed that baseline PCFS score was statistically significantly positively correlated to baseline SHAPS score ( = 0.070, = 0.045, 95% CI).
Our analysis revealed a significant relationship between measures of anhedonia and psychosocial functioning in adults with PCC. Strategies that aim to improve patient-reported outcomes with PCC need to prioritize the prevention and treatment of hedonic disturbances in patients experiencing PCC.
新冠后状况（PCC），也称为“长新冠”，其特征是持续存在的症状，对 PCC 患者的幸福感产生负面影响。快感缺失（即愉悦感降低）和社会心理功能受损是 PCC 患者的显著症状。我们旨在提供深入了解快感缺失和 PCC 患者社会心理功能受损的影响。
本事后分析使用了一项为期 8 周、双盲、随机、安慰剂对照试验的数据，该试验评估了沃替西汀对 PCC 患者认知缺陷的疗效（Clinicaltrials.gov 标识符：NCT05047952）。共有 147 名符合条件的参与者被随机分配接受沃替西汀或匹配的安慰剂，进行为期 8 周的双盲治疗。我们的研究调查了快感缺失与社会心理功能之间的关系，快感缺失通过 Snaith-Hamilton 快感量表（SHAPS）评估，社会心理功能通过新冠后功能状态（PCFS）量表评估。分析使用广义线性模型进行，调整了相关协变量，如年龄、性别、教育程度、疑似与确诊新冠诊断、MDD 诊断和饮酒。
在 147 名参与者中，有 143 名参与者有可用于分析的基线数据。我们观察到，基线 PCFS 评分与基线 SHAPS 评分呈统计学显著正相关（ = 0.070， = 0.045，95% CI）。
我们的分析揭示了 PCC 成人中快感缺失和社会心理功能之间存在显著关系。旨在改善 PCC 患者报告结局的策略需要优先考虑预防和治疗 PCC 患者的快感障碍。
